You are here

FDA Agrees to Design of Phase 3 Trial of Ancrod

EMERYVILLE, Calif., Aug. 22 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc., (NTI) (Nasdaq: NTII - News) today announced that it has reached agreement with the Food and Drug Administration (FDA) on the design of its Phase III clinical trial for Viprinex(TM) (Ancrod). FDA previously granted Fast Track Status to the overall Ancrod development program for acute ischemic stroke and now has additionally confirmed Fast Track Status for the clinical protocol.

Paul Freiman, president and CEO of NTI, said, "We anticipate patient enrollment in the trial to begin within the next few weeks. Our goal was to initiate the Phase III Program in the third calendar quarter of 2005 and we fully expect to achieve that goal. I could not be more proud of both the efforts and results of our team. Details of the trial will be made available upon initiation of the study. NTI obtained rights to Viprinex when it purchased Empire Pharmaceuticals in July 2004."

About Viprinex (Ancrod)
Derived from the venom of the Malayan pit viper, Viprinex is a thrombin- like enzyme that is highly specific to fibrinogen. When administered systemically, Viprinex has been shown to rapidly deplete plasma fibrinogen (it is a defibrinogenating agent). The effects are anticoagulation, improved blood viscosity and a secondary fibrinolytic or clot lysing action. Combined, these effects constitute a perfusion strategy that in prior human clinical trials appears to restore and enhance oxygen flow to the affected area of the brain.

Source: Neurobiological Technologies, Inc.

Recent Headlines

Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs